Author

N. Shakfa

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:mouse· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Approach:statistical model· 2 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Assay:imaging· 1

Frequent Co-Authors

M. Koti· 3 shared J. Wilson-Sanchez· 2 shared A. AfriyieAsante· 1 shared A. Asante· 1 shared A. Hamade· 1 shared A. O. Cudmore· 1 shared A. Tone· 1 shared B. C. Vanderhyden· 1 shared

Activity by Year

2019-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

M. Koti

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Comparative analysis of syngeneic mouse models of high-grade serous ovarian cancer

D. P. Cook, K. J. Galpin, G. M. Rodriguez, N. Shakfa, J. Wilson-Sanchez, M. Pereira, K. Matuszewska, J. Haagsma, H. Murshed, A. O. Cudmore, E. MacDonald, A. Tone, T. G. Shepherd, J. J. Petrik, M. Koti, B. C. Vanderhyden

The paper compares syngeneic mouse models of high-grade serous ovarian cancer to identify differences in signaling, metabolic, and functional properties, as well as tumor microenvironment variability.

bioRxiv · Mar 9, 2023Cancer Biology

PTEN and BRCA1 tumor suppressor loss associated tumor immune microenvironment exhibits differential response to therapeutic STING pathway activation in a murine model of ovarian cancer

N. Shakfa, D. Li, G. Conseil, E. D. Lightbody, J. Wilson-Sanchez, A. Hamade, S. Chenard, B. J. Laight, A. Asante, K. Tyryshkin, M. Köbel, M. Koti

This study examines how PTEN and BRCA1 loss in ovarian cancer affects tumor immune microenvironment response to STING pathway activation, showing improved survival in PTEN-deficient tumors with STING therapy.

bioRxiv · Jun 27, 2022 · PreprintImmunology

Chemotherapy induced immunogenic cell death alters response to exogenous activation of STING pathway and PD-L1 immune checkpoint blockade in a syngeneic murine model of ovarian cancer.

S. Nersesian, N. Shakfa, N. Peterson, T. Vidotto, A. AfriyieAsante, E. Lightbody, M. Koti

This study shows that chemotherapy type affects the response to STING pathway activation and PD-L1 blockade in a murine model of ovarian cancer, with carboplatin + STING + PD-L1 providing the best survival.

bioRxiv · Oct 30, 2019 · PreprintCancer Biology